Ah I see your point. I agree should, but not too confident about the would. It’s an interesting thought that a generic label should warn against prescription for CVD. I can almost imagine that prescribers might be dissuaded from off-label prescriptions based on fears of malpractice.
Of course then there’s a new issue: what happens when the reduce-it patents expire? FDA might be in a precarious position in 2030 when generics seek entry to the broader market.
Market Data 
Markets 
AI
